Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative ...

JIANGSU, China I July 27, 2025 I Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop ...

HONG KONG, China I July 28, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration ...

DAEJEON, South Korea I July 28, 2025 I Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal ...

STUTTGART, Germany I July 27, 2025 I La Merie Publishing released its newest product entitled: Fibroblast Activation Protein (FAP) Targeted Therapy: a ...

BASEL, Switzerland I July 25, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...

BRUSSELS, Belgium I July 24, 2025 I Precirix, a clinical-stage biopharmaceutical company focused on developing innovative targeted radiopharmaceutical ...

LONDON, UK I July 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced the approval of Blenrep in the European Union (EU) for the treatment of adults with ...

Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI™ (severe LAD-I), ...

GAITHERSBURG, MD, USA I July 24, 2025 I Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic ...

NEW YORK, NY, USA I July 24, 2025 I GNT Pharma, a late-stage biopharmaceutical company with operations in Seoul and New York, today announced its IND ...

PARIS, France I July 24, 2025 I Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable ...